Results 221 to 230 of about 67,058 (255)
Some of the next articles are maybe not open access.
Childhood Myelodysplastic Syndrome
Clinics in Laboratory Medicine, 2023Myelodysplastic syndrome (MDS) in children is rare, accounting for < 5% of all childhood hematologic malignancies. With the advent of next-generation sequencing, the etiology of many childhood MDS (cMDS) cases has been elucidated with the finding of predisposing germline mutations in one-quarter to one-third of cases; somatic mutations have also been ...
Karen M, Chisholm, Sandra D, Bohling
openaire +2 more sources
Seminars in Oncology Nursing, 1990
A cure for MDS has yet to be found. The aim of therapy is to attempt to restore normal hematopoiesis and prevent evolution to acute leukemia. The major trend is supportive care. Blood counts and bone marrow aspirations are taken to evaluate the disease, and transfusions of blood products and antibiotics are given when necessary.
A C, Yeomans, M T, Harle
openaire +2 more sources
A cure for MDS has yet to be found. The aim of therapy is to attempt to restore normal hematopoiesis and prevent evolution to acute leukemia. The major trend is supportive care. Blood counts and bone marrow aspirations are taken to evaluate the disease, and transfusions of blood products and antibiotics are given when necessary.
A C, Yeomans, M T, Harle
openaire +2 more sources
Current Opinion in Hematology, 1996
Myelodysplasia is being increasingly recognized as an important disease not only in the elderly but also in younger patients. It is also being seen more commonly as a complication of treatment with chemotherapeutic agents. Recent advances have distinguished between the different forms of therapy-related myelodysplasia as well as their genetic ...
openaire +2 more sources
Myelodysplasia is being increasingly recognized as an important disease not only in the elderly but also in younger patients. It is also being seen more commonly as a complication of treatment with chemotherapeutic agents. Recent advances have distinguished between the different forms of therapy-related myelodysplasia as well as their genetic ...
openaire +2 more sources
The Lancet, 2014
Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukaemia in a third of patients. 15% of cases occur after chemotherapy or radiotherapy for a previous cancer; the syndromes are most common in elderly people.
Lionel, Adès +2 more
openaire +2 more sources
Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukaemia in a third of patients. 15% of cases occur after chemotherapy or radiotherapy for a previous cancer; the syndromes are most common in elderly people.
Lionel, Adès +2 more
openaire +2 more sources
Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes
Leukemia & Lymphoma, 2007Thrombocytosis at diagnosis is uncommon in myelodysplastic (MDS) and myelodysplastic/myeloproliferative (MDS/MPD) syndromes. We conducted a retrospective analysis to determine the clinical and haematopathological features of such patients, and the effect of thrombocytosis on prognosis.
Dhatri, Kodali +4 more
openaire +2 more sources
Hypoplastic myelodysplastic syndrome
Cancer, 1988Over a period of 8 years 11 of 64 patients seen at Loyola University Medical Center with the diagnosis of myelodysplastic syndrome (MDS) also exhibited bone marrow hypoplasia (marrow cellularity of 25% or less) at presentation. The other 53 had normocellular or hypercellular marrow.
S, Nand, J E, Godwin
openaire +2 more sources
Blood, 2008
AbstractThere has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell.
openaire +2 more sources
AbstractThere has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell.
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2009
Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow disorders that affect mostly the elderly and have a variable probability of progression to acute leukemia. The diagnosis of MDS rests largely on a critical morphologic review of blood and bone marrow slides, with careful correlation with other clinical and essential laboratory ...
openaire +2 more sources
Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow disorders that affect mostly the elderly and have a variable probability of progression to acute leukemia. The diagnosis of MDS rests largely on a critical morphologic review of blood and bone marrow slides, with careful correlation with other clinical and essential laboratory ...
openaire +2 more sources
Oncogenes in the myelodysplastic syndrome
Blood Reviews, 1989The conversion of normal haemopoietic stem cells to myelodysplastic and then to leukaemic cells is marked by a number of events leading to progressive genetic changes in the abnormal clonal population. Cytogenetic evidence points to abnormalities at specific chromosomal locations, commonly involving chromosomes 5 and 7, where there are a particular ...
openaire +2 more sources